

## TransEnterix Appoints Theodore Pappas, MD Senior Surgical Officer

*New Senior Surgical Officer to enhance company's clinical and development efforts in minimally invasive surgical robotics*

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, announced today that it has appointed Theodore N. Pappas, MD as the company's Senior Surgical Officer. In this role, Dr. Pappas will work closely with management on clinical and regulatory strategy as well as guide continued development efforts to maximize surgical value.

This Smart News Release features multimedia. View the full release here:  
<http://www.businesswire.com/news/home/20160526006421/en/>



TransEnterix Appoints Theodore Pappas, MD Senior Surgical Officer (Photo: Business Wire)

University School of Medicine and a practicing surgeon in the Duke University Health System. Dr. Pappas will maintain his existing positions at Duke.

Dr. Pappas joined the Duke University School of Medicine in 1988 and has held numerous leadership positions in the school, Duke University Health System, Private Diagnostic Center, and the Veterans Administration Medical Center in Durham.

Dr. Pappas also serves as a member of the editorial board of several medical journals, including lead editor of the Atlas of Laparoscopic Surgery. He is a past president of the American Hepato-Pancreato-Biliary Association and serves as a senior director on the American Board of Surgery.

"I am very pleased to join TransEnterix in its efforts to advance surgery through the use of robotics," said Dr. Pappas. "The company and I share the vision that innovative technologies can provide surgeons with solutions to meaningful challenges in many different types of surgery."

### About TransEnterix

TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the development and commercialization of the ALF-X® System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye tracking camera control. The company is also developing the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform. The ALF-X has been granted a CE Mark, and is commercially available in Europe, but is not available for sale in the U.S. For more information, visit TransEnterix online at [www.transenterix.com](http://www.transenterix.com).

### Forward Looking Statements

"Dr. Pappas is a pioneer in advancing minimally invasive surgery and we are pleased that he has joined our team. He has co-authored over 300 peer-reviewed papers and book chapters, edited seven books and mentored over 225 general surgery, laparoscopic, and oncologic surgery residents and fellows," said Todd M. Pope, President and CEO of TransEnterix. "Dr. Pappas will help direct the clinical and development efforts of our robotic technology to have the greatest impact in advancing surgery around the world."

Dr. Pappas brings more than 30 years of experience at the highest levels of academic surgical innovation to TransEnterix. He is the Distinguished Professor of Surgical Innovation in the Duke

*This press release includes statements relating to the ALF-X® System, the SurgiBot™ System and our current regulatory and commercialization plans for these products. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations, including whether innovative technologies can provide surgeons with solutions to meaningful challenges in many different types of surgery. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 3, 2016, our Form 10-Q for the 2016 first quarter filed on May 10, 2016 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.*

View source version on [businesswire.com](http://www.businesswire.com/news/home/20160526006421/en/): <http://www.businesswire.com/news/home/20160526006421/en/>

Westwicke Partners

**Investor Contact:**

Mark Klausner, 443-213-0501

[invest@transenterix.com](mailto:invest@transenterix.com)

or

TransEnterix, Inc.

**Media Contact:**

Mohan Nathan, 919-765-8400

[media@transenterix.com](mailto:media@transenterix.com)

Source: TransEnterix, Inc.

News Provided by Acquire Media